National Cancer Institute (nci)

This large study of nearly 28,000 girls aged 12-16 tests whether a single dose of the HPV vaccine works as well as the standard two doses. HPV causes almost all cervical cancers, but many countries can't afford or manage multiple doses. If one dose is enough, it could make vaccin…

This study looks at whether giving the HPV vaccine on a different schedule—with a booster shot delayed by months—still protects against the virus. It involves 201 healthy girls and boys aged 9 to 11. Researchers will measure antibody levels over two years to see if the immune res…

This study tests a vaccine that helps the body's immune system recognize and attack advanced colon polyps, which can turn into cancer. About 110 people who have had these polyps removed will receive either the vaccine or a placebo. The goal is to see if the vaccine boosts immune …

This study tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer and whose tumors are PD-L1 negative. The goal is to see if the vaccine can train the immune system to recognize and…

This early-stage trial tests a DNA vaccine for people with long-term hepatitis C virus (HCV) infection. The vaccine is designed to help the immune system recognize and attack cells infected with HCV, potentially reducing the risk of liver cancer. About 33 participants will receiv…

This study tests a vaccine called Nous-209 in 45 people with Lynch syndrome, a genetic condition that raises the risk of colon and other cancers. The vaccine is made from man-made copies of proteins that cancer cells produce, aiming to teach the immune system to recognize and att…

This study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…

This study tests a treatment plan tailored to risk level for people with HIV and anal cancer. Low-risk patients receive standard chemotherapy and radiation, while high-risk patients also get the immunotherapy drug nivolumab to help prevent the cancer from returning. The goal is t…

This study tests a drug called crizotinib in people whose cancer has a specific genetic change called ROS1 translocation. The drug blocks a protein that may help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. Only 4 people took part,…

This early-phase study tests a new three-drug combination for adults with newly diagnosed acute myeloid leukemia (AML) who cannot receive standard chemotherapy. The treatment includes a targeted radiation antibody (lintuzumab-Ac-225) plus two oral drugs (venetoclax and ASTX-727).…

This study tested a three-part treatment for people with stage III non-small cell lung cancer that cannot be removed by surgery. The treatment combined standard chemotherapy (cisplatin, etoposide, docetaxel) and radiation with a drug called bevacizumab, which blocks blood flow to…

This large study looked at over 10,000 women with early-stage, hormone-sensitive breast cancer that had not spread to lymph nodes. It used a genetic test called Oncotype DX to see who could safely skip chemotherapy and just take hormone therapy. The goal was to find the best trea…

This study compares two drug combinations—melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR)—in 306 newly diagnosed multiple myeloma patients who cannot have high-dose therapy. The goal is to see which combination better delays cance…

This study tests whether adding an experimental drug (MK-2206) to standard hormone therapy (bicalutamide) works better than hormone therapy alone for men with prostate cancer whose PSA levels are rising after initial treatment. About 108 men with high-risk prostate cancer will ta…

This study tests a drug called selpercatinib in children and young adults (ages 1 to 21) whose cancers have a specific RET gene change. The goal is to see if the drug can shrink tumors or stop them from growing. Participants have advanced solid tumors, lymphomas, or related disor…

This study tests a drug called AZD1775 in people whose advanced cancers have a BRCA1 or BRCA2 gene mutation. The drug blocks a protein (WEE1) that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with various adva…

This study tests whether adding venetoclax to ASTX727 (a two-in-one pill) works better than ASTX727 alone for people with chronic myelomonocytic leukemia or related bone marrow cancers with too many immature cells. About 132 adults will be randomly assigned to one of the two trea…

This early-phase study tests a new drug (veliparib) combined with two chemotherapy drugs (cyclophosphamide and doxorubicin) in people with advanced solid tumors or non-Hodgkin lymphoma that cannot be removed by surgery or have spread. The main goal is to find the safest dose and …

This early-phase trial tests a combination of two drugs (erdafitinib and enfortumab vedotin) in about 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. The goal is to find the safest dose and see if the combo can shrink or stabilize the…

This study tests the drug avelumab in people with thymoma or thymic carcinoma that returned after platinum chemotherapy. Avelumab helps the immune system fight cancer. The goal is to see if it is safe and can shrink or slow tumor growth. About 56 adults will receive infusions eve…

This study tests whether adding the drug pomalidomide to standard chemotherapy helps people with a certain type of acute myeloid leukemia (AML) that is linked to a prior bone marrow disorder. The trial involves 50 newly diagnosed patients. The goal is to see if the combination le…

This study aimed to test a combination of two immunotherapy drugs (nivolumab and ipilimumab) in children, adolescents, and young adults with cancers that returned or didn't respond to treatment and had many genetic mutations. The goal was to see if the drugs could shrink or stabi…

This early-phase study tests a new combination of two immunotherapy drugs—pembrolizumab and recombinant interleukin-12—in adults with advanced solid tumors that have stopped responding to standard treatment. The main goal is to find the safest dose and check for side effects. Abo…

This study tests a drug called larotrectinib in children and young adults (ages 1 to 21) whose advanced or returning cancers have a specific gene change called an NTRK fusion. The goal is to see if the drug can shrink tumors or stop them from growing. Participants take the drug b…

This early-phase trial tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy before and after surgery is safe and feasible for people with resectable malignant pleural mesothelioma. 28 participants with stage I-III disease received the drug combinatio…

This early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…

This study tested two drugs—osimertinib and bevacizumab—in people with a specific type of lung cancer (EGFR mutation-positive) that had spread to the brain. The goal was to see if adding bevacizumab to osimertinib could help control the cancer longer. Only 5 patients took part, a…

This study tests a two-step treatment for people with stage II or III non-small cell lung cancer who are not healthy enough for surgery. First, they receive a shorter, higher-dose course of radiation. Then they get an immunotherapy drug called atezolizumab to help their immune sy…

This study tests two drugs, selumetinib and vinblastine, alone or together, in children and young adults (ages 2-25) with a type of brain cancer called low-grade glioma that has come back or not responded to treatment. The goal is to see if adding vinblastine to selumetinib works…

This study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced bladder or urinary tract cancer who cannot take standard cisplatin chemotherapy. About 72 adults with cancer that has spr…

This study tests whether adding an immunotherapy drug called atezolizumab to standard radiation therapy helps people with early-stage non-small cell lung cancer live longer. About 415 participants with stage I-IIA lung cancer will receive either radiation alone or radiation plus …

This early-stage trial tests a new drug (M3814) combined with three chemotherapy drugs for people whose acute myeloid leukemia has returned or not responded to standard treatment. The main goal is to find the best dose and check for side effects. About 48 adults will take part.

This study compares a standard chemotherapy drug (azacitidine) alone versus combined with either lenalidomide or vorinostat for people with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to see if adding another drug improves re…

This study is for people with a type of slow-growing lymphoma (grades 1-3a) that has returned or not responded to earlier treatment. It tests whether adding other drugs to a standard immunotherapy (obinutuzumab) can improve results. About 73 adults will receive different treatmen…

This study tests whether a combination of two oral medications (ASTX727 and venetoclax) can work as well as standard intravenous chemotherapy for younger adults (ages 18-65) with a high-risk form of acute myeloid leukemia (AML). The goal is to find a safe, effective dose and see …

This study tests whether adding berzosertib to standard chemotherapy (topotecan) helps people with relapsed small cell lung cancer live longer without their cancer growing. About 104 participants will receive either the combination or topotecan alone. The goal is to see if blocki…

This study tested the drug trametinib in 4 people with advanced cancers that have GNAQ or GNA11 gene mutations. Trametinib blocks certain proteins that help these cancers grow. The goal was to see if the drug could shrink tumors or stop them from getting worse.

This early-phase trial tests whether adding lenalidomide to standard chemotherapy (EPOCH) is safe and effective for adult T-cell leukemia-lymphoma (ATLL), a rare blood cancer linked to HTLV-1 infection. About 30 adults with certain subtypes of ATLL will receive the combination to…

This study tests the drug sunitinib in people with advanced cancers that have a specific change in the cKIT gene. Sunitinib works by blocking signals that make cancer cells grow. The trial includes about 10 adults with lymphoma, solid tumors, or multiple myeloma that have not res…

This study tests whether combining two drugs—axitinib (which blocks cancer cell growth) and nivolumab (which helps the immune system fight cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes a…

This early-phase trial tests a new drug called navtemadlin (KRT-232) combined with two standard drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has come back, not responded to treatment, or is newly diagnosed. The main goal is to find the safes…

This phase III trial tested two different schedules of the chemotherapy drug paclitaxel (weekly vs. every three weeks) combined with carboplatin, with or without the targeted drug bevacizumab, in 692 people with advanced ovarian, peritoneal, or fallopian tube cancer. The goal was…

This study tests the drug trametinib in 35 adults with advanced cancers that have certain BRAF gene mutations or fusions. Trametinib blocks proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. Participants must have alr…

This study tests whether adding the drug ipatasertib to standard hormone therapy (megestrol acetate) works better than hormone therapy alone for people with recurrent or metastatic endometrioid endometrial cancer. About 96 participants with grade 1 or 2 cancer will receive either…

This early-stage trial tests a new drug (ibrutinib) added to standard chemotherapy for HIV-positive people with a type of aggressive lymphoma. The goal is to find the safest dose and see if the combination can better control the cancer. About 46 participants are enrolled to help …

This phase III trial tested two different sequences of treatments for people with advanced melanoma that has a BRAF mutation and cannot be removed by surgery. One group started with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib),…

This early-stage study tested a combination of lenalidomide (a chemotherapy drug) and dinutuximab (an antibody therapy) with or without isotretinoin in 27 children whose neuroblastoma did not respond to treatment or came back. The main goal was to find the safest dose and underst…

This study tests a drug called afatinib in people with advanced cancers (like lymphoma or solid tumors) that have a specific change in the EGFR gene. The drug blocks signals that make cancer cells grow. The goal is to see if it can shrink tumors or stop them from growing after ot…

This study tests a new drug called TRC102 (methoxyamine) combined with standard chemotherapy (cisplatin and pemetrexed) in people with advanced solid tumors or mesothelioma that has not responded to prior treatment. The goal is to see if TRC102 can make cancer cells more sensitiv…

This study tests whether adding a third drug (bortezomib) to the standard two-drug combination (lenalidomide and dexamethasone) works better for people with newly diagnosed multiple myeloma who are not ready for a stem cell transplant. About 525 participants are randomly assigned…

This study tests a mix of three drugs (durvalumab, bevacizumab, tremelimumab) plus a procedure called TACE (which delivers chemotherapy beads to the liver) in people with advanced liver or bile duct cancer. The goal is to see if this combination can stop the cancer from growing f…

This study tests whether adding anetumab ravtansine to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with a rare cancer called malignant pleural mesothelioma that has a specific marker (mesothelin). The trial has two phases: first, finding …

This study is for adults with advanced cancers (like solid tumors or lymphoma) that have a specific genetic change called an NF2 mutation. The drug defactinib works by blocking a protein that helps these cancer cells grow. Researchers want to see if defactinib can shrink the tumo…

This study looks at whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can help control blood cancers like leukemia and lymphoma with fewer side effects. About 105 people aged 15-65 with high-risk blood cancers will receive a transplant from a …

This study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have come back or spread and have a specific change in the HRAS gene. The goal is to see if the drug can shrink tumors or stop them from growing. Participants must have measurable …

This study looks at whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer before and after surgery. About 278 adults with stage II to IVA cancer will take part. The…

This early-stage study tested the safety and best dose of vorinostat when given with the chemotherapy drug temozolomide in 83 adults with aggressive brain tumors called malignant gliomas. The goal was to see if combining these drugs could kill more tumor cells by making them more…

This study tests a drug called ado-trastuzumab emtansine in people whose cancers have too many HER2 receptors (HER2 amplification), but not breast or stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Researchers want …

This early-stage trial tested the safety and best dose of two drugs—cyclophosphamide and veliparib—given together to people with HER2-negative breast cancer that has spread or cannot be removed by surgery. The goal was to find the right dose for future studies and see if the comb…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with limited stage small cell lung cancer live longer. About 544 participants will receive either chemoradiation alone or chemoradiation plus atezolizumab. The goal is to s…

This study tests whether adding a drug called triapine to the standard radioactive treatment Lutathera works better than Lutathera alone for people with advanced neuroendocrine tumors that have spread. About 94 participants will receive either the combo or standard therapy. The g…

This study tests whether combining copanlisib and rituximab can slow or stop follicular lymphoma, a type of blood cancer, in people who haven't had treatment yet. About 33 participants will receive the drugs through an IV over up to 13 cycles. The goal is to see how many achieve …

This early-phase trial tested the safety of combining two drugs, nivolumab and cabozantinib, in 8 people with HIV who also have advanced solid tumors. The goal was to see if the combination is safe and can shrink or stabilize the cancer. The study focused on finding the right dos…

This study tests whether adding the immunotherapy drug durvalumab to standard chemoradiation, and continuing it afterward, helps people with stage III lung cancer that cannot be surgically removed live longer and keep the cancer from coming back. About 660 adults with newly diagn…

This study looks at whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women whose ovarian, fallopian tube, or peritoneal cancer has stopped responding to platinum-based chemo. About 582 women will take p…

This early-phase study tests a new drug called uproleselan combined with two standard chemotherapies for children and teens with leukemia that has returned or not responded to treatment. The drug aims to block cancer cells from hiding in the bone marrow, making chemotherapy more …

This study tests two immunotherapy drugs, atezolizumab and tiragolumab, in people with rare solid tumors that have spread or not responded to standard treatments. The goal is to see if the combination can shrink tumors and boost the immune system's attack on cancer. Researchers w…

This study tested three different drug combinations in 349 people with advanced (stage III or IV) or recurrent endometrial cancer. The goal was to see which combination worked best at stopping the cancer from growing or spreading. Participants received either paclitaxel/carboplat…

This study tests whether adding the drug cixutumumab to standard chemotherapy (paclitaxel) can help people with advanced esophageal or stomach-junction cancer live longer without their cancer growing. About 94 adults whose cancer has spread and who have already tried one treatmen…

This study tests whether the drug lenalidomide, combined with a vaccine, can help the immune system fight early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients with high-risk genetic features. About 49 participants will receive the treatme…

This study tests a combination of three drugs (darolutamide, leuprolide acetate, and exemestane) in people whose ovarian granulosa cell tumors have returned after treatment. The drugs work by blocking certain hormones that may help the tumor grow. The goal is to see if this combi…

This early-stage trial tests a combination of two drugs, duvelisib and nivolumab, in adults with advanced mycosis fungoides or Sézary syndrome (types of skin lymphoma). The goal is to find the safest and most effective dose and see if the combination can shrink tumors or reduce c…

This study tests whether adding an immunotherapy drug (nivolumab) to standard chemotherapy (paclitaxel) can better shrink tumors or delay cancer growth in people with angiosarcoma, a rare cancer of blood vessels. For patients who have already received taxane chemotherapy, the stu…

This study tests whether adding a drug called AZD1775 to standard chemotherapy (gemcitabine) helps women with ovarian cancer that has stopped responding to platinum-based treatments. The AZD1775 drug blocks a protein that cancer cells use to repair damage from chemotherapy, poten…

This study aimed to see if immune checkpoint drugs (nivolumab with or without ipilimumab) could help people with colorectal or gastroesophageal cancer delay or avoid major surgery. It planned to enroll adults with early-stage cancers. However, the study was withdrawn before any p…

This study looks at whether giving the HPV vaccine to adults before they get a kidney transplant helps their body fight HPV after the transplant. After transplant, patients must take strong drugs to prevent rejection, which weaken the immune system. The goal is to see if the vacc…

This early-phase study tests whether adding an experimental drug (ZEN003694) to two approved cancer drugs (cetuximab and encorafenib) is safe and effective for people with advanced colorectal cancer that has a specific BRAF V600E mutation and has stopped responding to standard tr…

This study tested whether the targeted drugs olaparib (alone or with cediranib) work better than standard platinum-based chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that came back after initial treatment. About 579 women with platinum-sensitive cance…

This study compares two chemotherapy regimens (carboplatin+paclitaxel vs oxaliplatin+capecitabine), each with or without the targeted drug bevacizumab, as first treatment for mucinous ovarian or fallopian tube cancer. About 50 people with newly diagnosed or recurrent disease took…

This early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The main goal is to find the safest dose and check for side effects. About 54 participants …

This study tests a drug called cabozantinib in people with osteosarcoma or Ewing sarcoma that has returned or worsened after standard treatment. The drug works by blocking enzymes that help cancer cells grow and by cutting off the blood supply tumors need. About 90 participants w…

This early-phase study tests the safety and best dose of combining entinostat (a drug that may stop cancer cell growth) with two immunotherapy drugs, nivolumab and ipilimumab, in people with advanced solid tumors that have spread or cannot be removed by surgery. The goal is to se…

This study tests two drugs, trametinib and GSK2141795, in people with advanced uveal melanoma that has spread. The goal is to see if the combination works better than trametinib alone at slowing cancer growth. About 42 adults with this rare eye cancer will take part.

This early-phase trial tests the safety and best dose of a new drug (BAY 1895344) when given with standard chemotherapy (irinotecan or topotecan) for people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic …

This study is for people with non-small cell lung cancer who have had chemotherapy and surgery. It tests whether adding a drug called AZD6738 to the immunotherapy drug durvalumab can help keep the cancer from coming back longer than durvalumab alone. About 630 adults with stage I…

This study compares giving the immunotherapy drug pembrolizumab both before and after surgery versus only after surgery for people with stage III-IV high-risk melanoma. The goal is to see if the combined approach improves event-free survival. About 313 participants are enrolled, …

This large phase 3 trial studied over 5,000 women with hormone receptor-positive, HER2-negative breast cancer that had spread to 1-3 lymph nodes. Participants received standard hormone therapy (tamoxifen or an aromatase inhibitor) either alone or with chemotherapy. The goal was t…

This study tests whether adding the immunotherapy drug cemiplimab to standard surgery (with or without radiation) helps people with advanced squamous cell skin cancer that can be surgically removed. About 420 adults with stage III or IV disease will be randomly assigned to receiv…

This early-stage study tests a combination of two drugs—trastuzumab deruxtecan (DS-8201a) and ceralasertib—in people with advanced solid tumors that have a HER2 mutation. The first part finds the safest dose and checks side effects. The second part compares the combo to DS-8201a …

This early-phase study tests whether combining a targeted drug (olaparib), an immunotherapy (durvalumab), and radiation therapy is safe for people with locally advanced pancreatic cancer that cannot be removed by surgery. About 18 participants will receive the combination after i…

This early-phase trial is testing a new drug (peposertib) combined with a radioactive treatment (lutetium Lu 177 dotatate) for people with a type of neuroendocrine tumor in the digestive system. The goal is to find the safest and most effective dose. About 29 adults with well-dif…

This study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…

This study is for people aged 65 and older with untreated chronic lymphocytic leukemia (CLL). It compares three treatment plans: two different drug combinations (bendamustine plus rituximab, or ibrutinib plus rituximab) versus ibrutinib alone. The goal is to see which approach wo…

This early-stage trial tests a drug called Z-endoxifen in 62 people with a type of breast cancer that has spread or come back. The drug works by blocking estrogen, which can fuel cancer growth. The main goal is to find the safest dose and understand side effects.

This study tests an oral drug (decitabine/cedazuridine) in people with BAP1 gene mutations who have early-stage mesothelioma. The goal is to see if the drug can stop the cancer from growing or shrink it. About 9 participants will take the drug and be monitored for safety and dise…

This study tests whether the drug trametinib can make radioactive iodine treatment more effective for people with advanced thyroid cancer that has stopped responding to standard therapy. About 34 adults with certain genetic types of thyroid cancer will receive trametinib followed…

This study tests whether adding the drug triapine to standard radiation and cisplatin chemotherapy helps women with advanced cervical or vaginal cancer live longer. About 450 women with newly diagnosed, bulky stage IB2 to IVA cervical cancer or stage II-IVA vaginal cancer will ta…

This study tests a drug called afatinib in 40 adults with advanced cancers that have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer cells from growing. The goal is to see if the drug can shrink tumors or s…

This study tests a drug called ulixertinib in children and teens whose advanced solid tumors, lymphoma, or histiocytic disorders have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the cancer. About 20 participants will receive…

This early-phase study tests a combination of two drugs—ipilimumab (an immunotherapy that helps the immune system attack cancer) and decitabine (a chemotherapy drug)—in people with myelodysplastic syndrome or acute myeloid leukemia that has returned or not responded to prior trea…

This early-stage trial tests a new drug called CA-4948 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with pancreatic cancer that has spread or cannot be removed by surgery. The goal is to find the safest dose and see if the combination can shrink …

This study tested two different doses of dexamethasone combined with lenalidomide in 452 people newly diagnosed with multiple myeloma, a type of blood cancer. The goal was to see which dose worked better at shrinking tumors. If the first treatment didn't work, patients could rece…

This early-stage trial is testing a new drug called peposertib combined with radiation therapy for people with advanced head and neck cancer who cannot take the standard chemo drug cisplatin. The study aims to find the safest dose and see if the combination helps shrink tumors. I…

This study is testing whether a mix of three immunotherapy drugs can shrink tumors in people with advanced HPV-related cancers, such as cervical, anal, and throat cancers. About 51 adults with cancers that have spread or not responded to standard treatments will receive the drugs…

This study tests a combination of two drugs—T-VEC, a virus-based therapy that attacks tumors, and pembrolizumab, an immunotherapy that helps the immune system fight cancer—in people with advanced melanoma that has worsened after prior treatment. About 43 participants with stage I…

This early-phase study tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in adults with advanced solid tumors that have spread or can't be removed. The main goal is to find the safest dose and check for side effects. About 66 people with cancers like col…

This study tests whether adding the immunotherapy drug pembrolizumab to the chemotherapy drug gemcitabine can help people with a type of bladder cancer that did not get better with standard BCG treatment. About 161 adults with non-muscle invasive bladder cancer will receive both …

This early-phase trial tested a combination of two targeted drugs, dabrafenib and lapatinib, in 23 people with advanced thyroid cancer that had a specific BRAF mutation and could not be removed by surgery. The main goal was to find the safest dose of lapatinib when given with dab…

This phase III trial tests whether adding the immunotherapy drug nivolumab after standard chemoradiation can help prevent anal cancer from coming back in patients with high-risk stage IIB to IIIC disease. About 344 adults will receive nivolumab or a placebo for up to six months. …

This study tests a new combination of drugs (Dara-SVD) for people with high-risk newly diagnosed multiple myeloma. It compares this new combo to the usual treatment. The goal is to see if adding selinexor early can lead to better cancer control. About 70 adults will take part in …

This early-phase study tests a combination of five drugs (VIPOR) in 14 adults with aggressive B-cell lymphoma that has spread to the brain or spinal cord. The main goal is to see if the treatment is safe enough for patients to complete at least two 21-day cycles without serious s…

This early-stage trial aimed to test a new drug called CB-5339 in people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The drug works by blocking certain enzymes that cancer cells need to grow. However, the study was withdrawn before …

This early-phase study tests a gel form of the drug endoxifen on women scheduled for breast surgery due to cancer or high risk. The goal is to find the safest dose and see how much drug reaches breast tissue. 32 women will apply the gel or a placebo daily for up to 4 weeks before…

This early-stage trial tests the safety and best dose of two oral drugs, ZEN003694 and binimetinib, taken together. It is for people with advanced solid tumors that have RAS pathway changes or triple-negative breast cancer that has spread or cannot be removed. The goal is to find…

This phase 3 study tests whether starting with immunotherapy alone (pembrolizumab) and adding chemotherapy only if the cancer worsens is better than starting with both immunotherapy and chemotherapy together for advanced non-squamous lung cancer. About 600 patients with stage IV …

This early-phase study tested an oral drug called triapine added to standard chemotherapy (cisplatin) and radiation for people with advanced cervical or vaginal cancer. The main goals were to find the safest dose and check how well the body absorbs the drug. Twenty-one participan…

This study tested a combination of two drugs—azacitidine and gemtuzumab ozogamicin—in 133 adults aged 60 and older with untreated acute myeloid leukemia (AML). The goal was to see how well the treatment could put the cancer into remission and help patients live longer. The approa…

This study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 women will receive one of s…

This study was designed to test a new drug called CBX-12 in people with advanced colorectal cancer that had stopped responding to standard treatments. The drug uses a special peptide to deliver a cancer-killing substance directly to tumor cells. However, the trial was withdrawn b…

This study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer growth enzymes or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the …

This study tests a drug called DS-8201a (trastuzumab deruxtecan) in children, teens, and young adults whose osteosarcoma, Wilms tumor, or desmoplastic small round cell tumor has come back or not responded to treatment. The drug works like a smart bomb, attaching to cancer cells a…

This study looks at whether taking iberdomide after CAR-T cell therapy can help people with multiple myeloma live longer without their cancer getting worse. About 78 participants will either receive iberdomide or just be monitored. The goal is to see if this drug boosts the immun…

This study tests whether adding the drug veliparib to standard chemotherapy and radiation helps people with stage III lung cancer that can't be removed by surgery. About 53 adults took part to find the best dose and see if the combination slows cancer growth. The goal is to impro…

This study compares three different drug combinations for people with advanced head and neck cancer that has spread or come back, and has stopped responding to immunotherapy. About 430 adults will receive either standard chemotherapy plus cetuximab, chemotherapy plus bevacizumab,…

This early-phase trial tests a new drug called navtemadlin (KRT-232) combined with standard chemotherapy (cytarabine and idarubicin) in 24 adults with newly diagnosed acute myeloid leukemia (AML). The main goal is to find the safest dose and check for side effects. Navtemadlin bl…

This study compares a new two-drug combination (olaparib and temozolomide) to the usual chemotherapy for people with advanced uterine leiomyosarcoma that has continued to grow after initial treatment. The goal is to see if the new combination can shrink or stabilize the cancer lo…

This study tests a drug called copanlisib in people whose cancers have a specific genetic mutation (PIK3CA). The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with advanced or hard-to…

This study tested a combination of two drugs—entinostat and aldesleukin—in 47 people with kidney cancer that had spread. The goal was to see if adding entinostat could make the standard immune-boosting treatment work better. The trial looked at safety and how well the tumors shra…

This study tests whether pembrolizumab, an immunotherapy drug that helps the immune system fight cancer, can prevent bladder or urinary tract cancer from returning after surgery. About 739 people with muscle-invasive or locally advanced cancer are randomly assigned to receive the…

This study tests a new drug combination for people with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based chemotherapy. About 96 participants will receive either the standard drug paclitaxel or the experimental drug anetumab ravtansine, b…

This study tested whether adding a targeted drug (bevacizumab) to standard chemotherapy helps prevent colon cancer from coming back in people with high-risk stage II colon cancer after surgery. About 2,400 participants were randomly assigned to receive either chemotherapy alone o…

This study tests a drug called MLN0128 (TAK-228) in 49 adults with advanced cancers that have TSC1 or TSC2 mutations. The drug works by blocking enzymes that help cancer cells grow. Researchers will check if tumors shrink or stop growing, and track how long patients live or stay …

This study tested a drug called atezolizumab in 27 people with rare cancers of the bone (chondrosarcoma) or soft tissue (clear cell sarcoma) that could not be removed by surgery or had spread. The drug helps the body's immune system attack cancer cells. The main goal was to see i…

This early-phase study tests a combination of two targeted drugs (vismodegib and erlotinib) with or without a standard chemotherapy drug (gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the s…

This study tests a drug called elimusertib in children and young adults (ages 1 to 30) whose solid tumors have come back or stopped responding to treatment. The drug works by blocking enzymes that help cancer cells grow. The goal is to find the safest dose and see if it can shrin…

This study tested whether taking lenalidomide (a drug that helps the immune system fight cancer) after a stem cell transplant could delay the return of multiple myeloma. About 460 patients who had already received a transplant were randomly given either lenalidomide or a placebo.…

This early-phase trial tests a new two-drug combination (sapanisertib and osimertinib) in 36 adults with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to standard treatment. The main goal is to find the safest dose and identify side effects. This is …

This early-phase study tests a new drug called berzosertib (M6620) alongside standard chemotherapy (cisplatin) and radiation for people with advanced head and neck cancer that has spread to nearby tissues or lymph nodes. The main goal is to find the safest dose and check for side…

This study tests a drug called ibrutinib in people with stage IV melanoma (skin cancer that has spread) that did not get better with other treatments. Ibrutinib works by blocking certain enzymes that cancer cells need to grow. The main goal is to see if the drug can shrink tumors…

This study tests an HPV vaccine (PRGN-2009) alone or combined with a drug called M7824 in people with HPV-positive cancers that have spread or come back. The goal is to find a safe dose and see if the combination boosts the immune system to fight the cancer better. Participants r…

This study is for people aged 75 or older who have been newly diagnosed with certain aggressive types of B-cell lymphoma. It tests whether adding an oral medication (CC-486, or oral azacitidine) to the standard reduced-dose chemotherapy regimen (R-miniCHOP) can help keep the canc…

This study tested whether adding lenalidomide to standard chemoimmunotherapy (R-CHOP) helps people with newly diagnosed, advanced diffuse large B-cell lymphoma. About 349 participants received either R-CHOP alone or R-CHOP plus lenalidomide. The goal was to see if the combination…

This study tests two drug combinations (belinostat plus either guadecitabine or ASTX727) in 19 adults with a rare bone cancer called chondrosarcoma that cannot be surgically removed and has spread. The goal is to see if the drugs can shrink tumors or stop them from growing. Parti…

This early-phase trial tests the safety and best dose of combining two drugs, ibrutinib and palbociclib, in adults with mantle cell lymphoma that has come back after prior treatment. The drugs work by blocking enzymes that cancer cells need to grow. The study aims to find a dose …

This early-phase study tests a new three-drug combination (tazemetostat, dabrafenib, and trametinib) in people with advanced BRAF-mutated melanoma that has stopped responding to standard BRAF/MEK inhibitor therapy. The goal is to find the best dose and see if the combo can shrink…

This study tests whether a drug called olaparib (a PARP inhibitor) works better alone or combined with atezolizumab (an immunotherapy) for people with advanced breast cancer that has a BRCA mutation and is not HER2-positive. About 81 participants with locally advanced or metastat…

This study is for adults aged 18 to 75 with a specific type of leukemia called BCR-ABL-positive acute lymphoblastic leukemia (ALL). It compares the usual treatment (steroids, a targeted drug, and chemotherapy) with the same treatment plus an extra drug called blinatumomab. The go…

This study tests a drug called selumetinib in children and young adults with low grade glioma that has come back or not responded to other treatments. The drug works by blocking certain enzymes that help tumor cells grow. The goal is to find the best dose and see if it can shrink…

This study tests whether adding an experimental drug (M6620) to standard chemotherapy can better shrink tumors or slow the disease in men with advanced prostate cancer that no longer responds to hormone therapy. About 73 participants will receive either M6620 plus carboplatin or …

This study tests a drug called copanlisib in 35 adults with advanced or hard-to-treat cancers that have a specific change in the PTEN gene. The drug blocks a protein that helps cancer cells grow. The main goal is to see if the tumors shrink or stop growing.

This study tests two targeted drugs, palbociclib and binimetinib, in people with cancers that have RAS mutations, including certain ovarian and pancreatic cancers. The goal is to see if the combination can slow cancer growth better than one drug alone. About 199 adults will take …

This phase 3 trial compares two treatments for people with a bone marrow disorder called myelodysplastic syndrome (MDS) who have low red blood cell counts (anemia). One group gets lenalidomide alone, the other gets lenalidomide plus epoetin alfa, a drug that stimulates red blood …

This study tests whether adding the drug veliparib to standard chemotherapy (gemcitabine and cisplatin) works better than chemo alone for people with advanced pancreatic cancer who have BRCA or PALB2 gene mutations. About 83 participants will be enrolled. The goal is to see if th…

This study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…

This study tests whether the immunotherapy drug atezolizumab, alone or with bevacizumab, can shrink tumors in people with advanced alveolar soft part sarcoma that cannot be removed by surgery. About 63 participants will receive the treatment. The goal is to see if the cancer resp…

This study tests a drug called trametinib in 50 patients whose cancers have a specific genetic change called an NF1 mutation. The drug blocks certain proteins that help cancer cells grow. The goal is to see if trametinib can shrink tumors or stop them from growing.

This study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which blocks cancer cell repair)—works better than olaparib alone for people with certain ovarian, fallopian tube, peritoneal, or triple-negative breast cancers that have …

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or cannot be removed. The main goal is to find the safest dose and understand side effects. The study enrolls 39 adults with specif…

This study tests a drug called ipatasertib in 35 adults with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an AKT mutation. The drug works by blocking a protein that helps cancer cells grow. The main goal is to see if the tumors shrin…

This study tests a drug called tazemetostat in people whose ovarian or endometrial cancer has returned after previous treatment. The drug works by blocking a protein that helps cancer cells grow. The goal is to see if it can shrink tumors or stop them from growing. About 62 parti…

This early-phase study tests a combination of three drugs (venetoclax, ixazomib, and dexamethasone) in 24 people with light chain amyloidosis that has come back or not responded to prior treatment. Participants must have a specific genetic change called t(11;14). The goal is to f…

This study tests whether adding venetoclax to standard chemotherapy can help prevent aggressive lymphomas from coming back or getting worse. About 363 adults with certain high-grade B-cell lymphomas will receive either the usual chemo or the usual chemo plus venetoclax. The goal …

This early-phase trial tests a new drug called selinexor alongside standard radiation and chemotherapy for people with newly diagnosed glioblastoma, a fast-growing brain cancer. The main goal is to find the highest safe dose of selinexor that can be given with these treatments. A…

This study tested two different doses of the immunotherapy drug ipilimumab, either alone or combined with high-dose interferon, in 88 people with advanced melanoma that could not be surgically removed. The goal was to see if the combination could delay cancer growth better than i…

This study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with a short course of radiation can completely eliminate advanced rectal cancer before surgery. About 31 adults with a specific genetic type (MSI-H/dMMR) of stage II or III rectal cancer wil…

This study tests whether the drug crizotinib can shrink or slow advanced or treatment-resistant cancers (solid tumors, lymphoma, or multiple myeloma) that have a specific genetic change called MET amplification. About 44 adults will receive crizotinib, which blocks signals that h…

This early-stage trial tests a combination of three drugs—tazemetostat, topotecan, and pembrolizumab—in adults with small cell lung cancer that has returned after treatment. The goal is to find the safest dose and see if the combination can shrink or stabilize the cancer. About 1…

This study tests whether adding the drug decitabine to standard chemotherapy can help more adults with acute myeloid leukemia (AML) achieve remission. About 178 participants will receive either low or high doses of decitabine alongside chemo drugs. The goal is to see if this appr…

This early-stage study is testing a combination of three drugs (alisertib, bortezomib, and rituximab) in about 24 people with mantle cell or low-grade non-Hodgkin lymphoma that has returned or stopped responding to prior treatments. The main goal is to find the safest dose of the…

This study tests an experimental pill called alvelestat in people who developed a serious lung condition (bronchiolitis obliterans syndrome) after a stem cell transplant. The goal is to find a safe dose that blocks a harmful enzyme and improves lung function. About 14 adults with…

This study tested two different doses of imatinib and another drug called dasatinib in 406 people newly diagnosed with chronic phase chronic myeloid leukemia (CML). The goal was to see which treatment best reduced cancer cells to very low levels after one year. All participants h…

This early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…

This study looks at whether the immunotherapy drug nivolumab can eliminate leftover cancer cells and prevent relapse in adults with acute myeloid leukemia (AML) who are already in remission after chemotherapy. About 82 participants will receive either nivolumab or standard care. …

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard radiation therapy helps prevent endometrial cancer from coming back in people with early-stage disease. About 164 participants with high-intermediate risk features will receive either radiation alon…

This study tests whether adding talazoparib to atezolizumab helps control extensive-stage small cell lung cancer better than atezolizumab alone. About 103 adults with a specific genetic marker (SLFN11-positive) are participating. The goal is to see if the combination slows cancer…

This early-stage trial tests a new drug (BAY 1895344) combined with standard chemotherapy for people with advanced solid tumors, especially bladder cancer. The goal is to find the safest dose and see how well the combination works. About 74 adults with cancers like lung, ovarian,…

This study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with advanced, recurrent, or metastatic endometrial cancer. The goal was to see if the combo could slow or stop cancer growth. Cabozantinib blocks enzymes that help tumors grow, while nivolumab…

This study tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with radiation therapy can shrink tumors in people with metastatic colorectal or non-small cell lung cancer. About 110 adults with advanced cancer that has spread will receive the drugs alone…

This study is for people with a certain type of advanced colorectal cancer that has spread (metastatic dMMR/MSI-H). It compares two treatments: one uses the immunotherapy drug atezolizumab alone, and the other combines atezolizumab with standard chemotherapy and a drug that block…

This phase 3 trial tests whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with muscle-invasive bladder cancer live longer without their cancer returning or needing bladder removal. About 475 adults with localized disease are participating…

This study tests a drug called binimetinib in 53 adults with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an NRAS mutation. The drug blocks proteins that help cancer grow. The main goal is to see if the drug can shrink tumors or stop…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced or recurrent endometrial cancer live longer without the disease getting worse. About 800 participants with stage III, IV, or recur…

This study tests a combination of two drugs, sacituzumab govitecan and berzosertib, in adults with small cell lung cancer or cancers that have stopped responding to PARP inhibitors. The goal is to find a safe dose and see if the combo can shrink tumors. Participants receive the d…

This phase II trial tests the drug pembrolizumab in people with a rare type of skin cancer called desmoplastic melanoma. The study includes patients whose tumors can be removed by surgery and those whose tumors cannot. The goal is to see if pembrolizumab can shrink or eliminate t…

This early-phase study tests the safety and best dose of a drug called copanlisib combined with immunotherapy drugs (nivolumab, with or without ipilimumab) in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. Copanlisib blocks proteins t…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy works better than chemotherapy alone for people with anal cancer that has spread. About 205 adults with inoperable or metastatic anal cancer will receive either the combination or standard t…

This study tests whether adding two targeted drugs (atezolizumab and bevacizumab) to standard chemotherapy helps people with a rare, advanced liver cancer live longer without their disease getting worse. About 88 adults with cancer that cannot be surgically removed will be random…

This study tests whether combining two immunotherapy drugs, nivolumab and ipilimumab, can shrink tumors in people with rare cancers. About 800 participants with over 50 different rare tumor types received these drugs to boost their immune system's ability to fight cancer. The goa…

This study tests whether adding a targeted drug called ganitumab to standard chemotherapy helps people with newly diagnosed Ewing sarcoma that has spread. The trial includes 312 participants and aims to see if the combination improves survival without the cancer growing back. The…

This study tests a pill called osimertinib in people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an EGFR mutation. The drug blocks a faulty protein that helps cancer grow. The goal is to see if the drug can shrink or slow the c…

This study looked at adding the drug pazopanib to standard radiation or chemoradiation before surgery for patients with certain soft tissue sarcomas. The goal was to see if the combination is safe and helps shrink tumors more effectively. About 140 adults and children with newly …

This study tested a new drug called veliparib, given with radiation and chemotherapy, for children and young adults with a fast-growing brain tumor (high-grade glioma). The goal was to see if adding veliparib helps keep the cancer from coming back longer than standard treatment. …

This early-phase trial tests adding a targeted drug called ipatasertib to standard chemotherapy (paclitaxel and carboplatin) for people with stage III or IV ovarian cancer. The goal is to find the safest dose and see if the combination can better control tumor growth. About 25 pa…

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (azacitidine and venetoclax) can improve outcomes for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemo. About 60 participants will be rando…

This study tested whether adding the drug entinostat to standard hormone therapy (exemestane) helps people with advanced hormone receptor-positive breast cancer live longer without their cancer growing. About 600 adults with breast cancer that had spread or come back took part. T…

This early-phase trial tested a combination of a BET inhibitor (ZEN003694) with immunotherapy drugs (nivolumab with or without ipilimumab) in people with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see if the combo…

This study tests two drugs—olaparib and temozolomide—together in 23 people with advanced uterine leiomyosarcoma that has spread or cannot be removed by surgery. Olaparib blocks a protein that helps cancer cells repair themselves, while temozolomide damages cancer cell DNA. The go…

This study tested a combination of the immunotherapy drug blinatumomab with either standard chemotherapy or dasatinib and prednisone in adults aged 65 and older with acute lymphoblastic leukemia (ALL). The goal was to see if the combination could improve survival and control the …

This study tests an oral drug called cabozantinib in children and young adults (up to age 30) with sarcomas, Wilms tumor, or other rare cancers that have come back or not responded to treatment. The drug works by blocking certain enzymes that help tumors grow and form blood vesse…

This study tests whether adding a third drug (venetoclax) to a two-drug combination (ibrutinib and obinutuzumab) helps younger adults with untreated chronic lymphocytic leukemia (CLL) live longer without their cancer getting worse. About 720 participants will receive either the t…

This study tests a drug called selumetinib in adults with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink these tumors or slow their growth. Participants take the drug twice daily and are monitored …

This study tests whether adding an immunotherapy drug (tremelimumab) to a targeted therapy (olaparib) helps control recurrent ovarian, fallopian tube, or peritoneal cancer better than olaparib alone. About 61 adults with platinum-sensitive cancer are participating. The goal is to…

This study tests whether adding cediranib to olaparib works better than olaparib alone for men with a hard-to-treat prostate cancer that has spread. About 90 men will take part. The goal is to see if the combination can slow cancer growth longer. Both drugs target cancer cells in…

This study tests if bevacizumab, a drug that blocks blood vessel growth, can help adults with recurrent respiratory papillomatosis (RRP) go longer between surgeries to remove wart-like growths in their airways. About 21 participants who need at least two surgeries per year will r…

This study tests whether adding cabozantinib to the immunotherapy drug nivolumab can prevent mucosal melanoma from returning after surgical removal. About 100 adults with this rare cancer will receive either nivolumab alone or nivolumab plus cabozantinib. The goal is to see which…

This phase III trial tests whether adding cabozantinib to avelumab (an immunotherapy) helps people with metastatic urothelial cancer live longer than avelumab alone. About 654 participants who have already completed initial chemotherapy will receive either the combination or avel…

This early-phase trial tests the safety and best dose of two drugs—MK-2206 and hydroxychloroquine—given together to people with advanced solid tumors, melanoma, prostate, or kidney cancer. The goal is to see if blocking certain cell signals and a process called autophagy can slow…

This study tests a drug called copanlisib in 22 adults with various cancers that have lost a protein called PTEN. The drug works by blocking enzymes that help cancer cells grow and survive. The main goal is to see if the drug can shrink tumors or stop them from growing for at lea…

This study tests a drug called telaglenastat (CB-839) in about 54 adults with advanced solid tumors or malignant peripheral nerve sheath tumors that have specific genetic changes (NF1, KEAP1/NRF2, or LKB1 mutations). The drug works by blocking an enzyme that cancer cells need to …

This study tests a drug called selumetinib in children and young adults (ages 3-18) with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink or slow the growth of these tumors. Participants take the dru…

This study tests a drug called AZD5363 in 35 adults whose cancers have a specific genetic change (AKT mutation). The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. Participants have advanced solid tum…

This study tests whether combining two drugs, talazoparib and temozolomide, can shrink or stop the growth of rare cancers that have spread. The drugs work by damaging cancer cell DNA and blocking its repair. The trial includes 14 adults with advanced rare solid tumors, like pheoc…

This early-phase trial tests a new drug called telaglenastat combined with standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The main goal is to find the safest dose and see if the combination helps shrink tumors. About …

This study aimed to test a combination of two drugs, tarlatamab and sacituzumab govitecan, in adults with extensive-stage small cell lung cancer or extrapulmonary neuroendocrine cancer that had returned or not responded to prior treatment. The goal was to see if the combination w…

This early-phase trial tests the safety and best dose of the drug trametinib when given with or without whole-brain radiation for people with cancer that has spread to the brain. Trametinib blocks certain enzymes that help cancer cells grow, and radiation uses high-energy X-rays …

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can improve outcomes for people with stage III bladder cancer that has spread to nearby lymph nodes. The goal is to see if the combination helps shrink tumors and allows patie…

This study tests whether combining two drugs, lurbinectedin and berzosertib, can shrink tumors in people with small cell lung cancer or high-grade neuroendocrine cancers. These cancers often stop responding to standard chemotherapy. The trial includes 37 adults and aims to find t…

This study tests a drug called sapanisertib in 17 people with advanced bladder cancer that has a specific change in the TSC1 or TSC2 gene. The drug works by blocking a protein that helps cancer cells grow. The main goal is to see if the drug can shrink tumors or stop them from gr…

This early-phase trial tests the safety and best dose of a drug called birinapant when given together with a precise type of re-radiation for people whose head and neck cancer has returned near its original spot. The drug blocks a protein that helps cancer cells survive, while th…

This study tests a drug called erdafitinib in people whose cancers have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with advanced or hard-t…

This study tests whether a cancer-killing virus (T-VEC) combined with radiation can shrink soft tissue sarcomas before surgery. About 40 adults with newly diagnosed, removable sarcomas will receive the virus injected into the tumor plus radiation. The main goals are to see how ma…

This study tests whether the drug pazopanib can delay or prevent kidney cancer from returning in patients who have had all visible tumors surgically removed. About 129 adults with advanced kidney cancer that spread to other parts of the body but was fully removed by surgery will …

This study tests a drug called M1774 in 20 men with advanced prostate cancer that has a specific gene change (SPOP mutation) and has stopped responding to other treatments. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if M1774 can shr…

This study compared pembrolizumab (Keytruda) to the usual treatments (high-dose interferon or ipilimumab) in over 1,300 people with high-risk melanoma that was surgically removed. The goal was to see if pembrolizumab could better prevent the cancer from coming back or spreading. …

This study tested the drug crizotinib in 5 patients with advanced cancers that have a specific genetic change called ALK rearrangement. The goal was to see if the drug could shrink or stop the growth of these tumors. The approach uses a targeted therapy to block a protein that he…

This phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.

This study is testing a two-step treatment for people with rare skin cancers or certain lymphomas that have not responded to standard therapies. First, patients receive a virus-based drug (talimogene laherparepvec) injected directly into tumors. Then, they also get an immunothera…

This study tests a combination of six drugs (TEDDI-R) for people whose aggressive B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this mix can control the cancer better than current treatments. About 48 adults with relapsed or refractory disease will…

This early-phase study tests a combination of three drugs—rituximab, lenalidomide, and ibrutinib—in people with untreated follicular lymphoma, a slow-growing blood cancer. The main goal is to find the safest dose and understand side effects. About 33 participants with stage II to…

This study tested adding vorinostat to the standard R-CHOP treatment for people with newly diagnosed advanced diffuse large B-cell lymphoma (DLBCL). The goal was to find the safest dose and see if the combination helps keep cancer from coming back. 83 participants received the dr…

This phase 2 trial tests whether adding pembrolizumab (an immunotherapy) to olaparib (a targeted therapy) works better than olaparib alone for controlling metastatic pancreatic cancer in people with inherited BRCA1 or BRCA2 mutations. About 88 participants will receive either the…

This study tests a drug called pomalidomide in 45 people with Kaposi sarcoma, a rare skin cancer. The drug works by cutting off blood supply to tumors and boosting the immune system to kill cancer cells. The goal is to see if the drug can shrink tumors and keep them from growing …

This study tests a drug called vismodegib in people with advanced or treatment-resistant cancers (solid tumors, lymphoma, or multiple myeloma) that have specific mutations in the SMO or PTCH1 genes. The drug blocks a protein that helps cancer grow. The goal is to see if the drug …

This study tests two drugs, eribulin and copanlisib, together in people with metastatic triple-negative breast cancer that has spread or cannot be removed. The goal is to find the safest dose and see if the combination helps stop or slow tumor growth better than eribulin alone. A…

This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in 59 people with advanced solid tumors, including melanoma, colorectal, ovarian, and k…

This study tests whether adding iadademstat to the drug ASTX727 works better than ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of blood cancers. About 62 adults whose cancer has progressed to a more aggressive phase will be randomly assigned…

This early-stage study tests a mix of six drugs (called ViPOR-P) in adults with B-cell lymphomas that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. About 34 participants will take pills and receive infusions o…

This study compares a new targeted drug, selumetinib, to standard chemotherapy (carboplatin/vincristine) in children and young adults (ages 2-21) with NF1-related low-grade gliomas. The goal is to see if selumetinib works as well or better at controlling tumor growth and improvin…

This early-phase trial tests the safety of giving people with multiple myeloma their own genetically modified T cells. The cells are reprogrammed to better recognize and attack myeloma cells. The study enrolls 35 adults whose cancer has not responded to standard therapies. Partic…

This study tests two drugs that lower or block male hormones to slow or shrink a rare type of salivary gland cancer that has spread or come back. About 21 people whose cancer has male hormone receptors and who have not had hormone therapy before will take darolutamide pills and g…

This study tests a pill called erdafitinib in 35 adults whose cancers have specific FGFR gene mutations or fusions. The drug blocks a faulty protein that helps cancer grow, potentially shrinking tumors or slowing the disease. It is a phase 2 trial for advanced solid tumors that h…

This study tests whether a newer drug, Z-Endoxifen, works better than the standard tamoxifen for postmenopausal women with advanced ER+/HER2- breast cancer. About 81 participants will receive one of the two hormone therapies to see which delays cancer growth longer. The goal is t…

This study tests a drug called ibrutinib in 44 people whose hairy cell leukemia has come back after treatment. Ibrutinib works by blocking a protein that cancer cells need to grow. The main goal is to see how many patients have their cancer shrink or disappear within 32 weeks.

This study tests whether a stem cell transplant from a healthy donor can safely treat people with severe T-cell problems. Participants receive chemotherapy and antibody therapy before the transplant to prepare their body, then donor stem cells are given to build a new, healthy im…

This early-phase study tested a vaccine therapy given directly into the tumor along with a growth factor to boost the immune system in 18 people with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effe…

This study tests whether adding the experimental drug M6620 to standard chemotherapy (gemcitabine) works better than gemcitabine alone for women with ovarian, peritoneal, or fallopian tube cancer that has returned after platinum-based treatment. About 70 participants are randomly…

This study tested whether adding a drug called GM-CSF (sargramostim) to the immunotherapy ipilimumab helps people with advanced melanoma that cannot be removed by surgery. About 245 participants received either the combination or ipilimumab alone. The main goal was to see if the …

This study tests the safety and best dose of adding telaglenastat to the standard drug osimertinib for people with stage IV non-small cell lung cancer that has a specific EGFR mutation. The two drugs work together to block enzymes that cancer cells need to grow. The trial involve…

This study tests two drugs, trametinib and navitoclax, in people with advanced solid tumors that have specific changes in the KRAS or NRAS genes. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. About 96 participants will take…

This study compares three different drug combinations in 444 people with ovarian, fallopian tube, or primary peritoneal cancer that came back after platinum chemotherapy. The drugs include a standard chemotherapy (pegylated liposomal doxorubicin) plus one or two immune-boosting o…

This study tests a new combination of drugs for people with advanced squamous non-small cell lung cancer that has spread. The treatment includes a targeted drug (berzosertib), chemotherapy (carboplatin and gemcitabine), and an immunotherapy (pembrolizumab). The goal is to find th…

This early-stage trial tests the safety and best dose of combining two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study includes about 48 adults with various types of non-Hodgkin lymphoma. Resea…

This study tests a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers have come back or are not responding to treatment and have specific changes in FGFR genes. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see …

This study tested two drugs, erlotinib and cabozantinib, given alone or together in 125 people with advanced non-small cell lung cancer that had already been treated. The goal was to see if the combination worked better than either drug alone at slowing cancer growth. Participant…

This study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …

This study tested a drug called vismodegib in 45 people with advanced chondrosarcoma, a rare bone cancer that has spread and is hard to treat. The goal was to see if the drug could shrink tumors or stop them from growing for at least 6 months. Researchers measured how many patien…

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or can't be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the drug combo can shrink tum…

This large phase 3 study tested whether the immunotherapy drug ipilimumab works better than high-dose interferon alfa-2b at preventing melanoma from coming back after surgery. Over 1,600 patients with high-risk stage III or IV melanoma that had been completely removed took part. …

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can better eliminate leftover cancer cells in adults newly diagnosed with acute myeloid leukemia (AML). About 49 participants receive either chemo alone or chemo plus pembrolizumab. The …

This study tests a drug called adavosertib in adults with advanced solid tumors that have a missing or broken SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.

This study tests whether giving the immunotherapy drug nivolumab before and after kidney cancer surgery can prevent the cancer from returning. About 819 people with localized kidney cancer that has not spread far are participating. The goal is to see if adding nivolumab to standa…

This early-stage trial tests a new drug called MEDI-570 in people with certain types of T-cell lymphoma that have returned or not responded to prior treatments. The main goals are to find the safest dose and understand side effects. The drug works by helping the immune system att…

This early-phase study tested a new way of giving two cancer drugs—adavosertib and olaparib—one after the other, instead of together, in 13 people with advanced solid tumors that have specific DNA repair mutations. The goal was to find the best dose and see if this approach could…

This early-phase trial tested the safety and best dose of two drugs, vorinostat and azacitidine, given together to adults with advanced nasopharyngeal cancer or a rare nasal lymphoma that had come back or spread. The goal was to find a dose that limits side effects while potentia…

This early-phase study tested a combination of three drugs—bortezomib, sorafenib, and decitabine—in 15 adults with acute myeloid leukemia (AML), including older patients or those whose cancer returned. The main goal was to find the safest dose and check for side effects. Research…

This study tested a combination of two drugs, vorinostat and azacitidine, in 135 people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The goal was to find the best dose and see how well the drugs work together to stop cancer cell growth. While the treatmen…

This early-phase study tests a combination of four drugs (atezolizumab, gemcitabine, oxaliplatin, and rituximab) in about 24 people with transformed diffuse large B-cell lymphoma that has come back or stopped responding to treatment. The main goals are to find the safest dose and…

This study tests a new drug, PEN-866, combined with two standard chemotherapy drugs (vincristine and temozolomide) for adolescents and young adults aged 12-39 whose solid tumors, including Ewing sarcoma and rhabdomyosarcoma, have returned or not responded to standard treatments. …

This study tests whether combining immunotherapy drugs (nivolumab with or without ipilimumab) with precise radiation can help people with recurrent high-grade meningioma, a type of brain tumor. About 38 adults whose tumor returned after prior radiation will receive the treatment.…

This study tests whether adding the drug ibrutinib before and after a stem cell transplant helps people with a specific type of lymphoma (activated B-cell diffuse large B-cell lymphoma) that has returned or not responded to treatment. About 94 participants will receive either ibr…

This study tests a drug called crizotinib in people with advanced cancers that have a specific genetic change (MET exon 14 deletion). The drug blocks enzymes that help cancer grow. About 20 participants will receive the treatment to see if their tumors shrink or stop growing.

This study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …

This study tested a personalized approach to dosing the drug pazopanib in 54 people with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find the dose that gives the best drug levels in the blood while limiting side effects. Res…

This early-phase study tests the safety of the immunotherapy drug atezolizumab given after a patient's own immune cells have been modified and infused back (adoptive cell transfer). It includes 40 adults with advanced blood or solid cancers that no longer respond to standard trea…

This study tests a new drug called pevonedistat, given alone or with standard chemotherapy, in people with advanced bile duct cancer of the liver that has spread or cannot be removed. The goal is to see if the combination can shrink tumors. About 40 adults who have already tried …

This study tests whether taking a break from two targeted melanoma drugs (dabrafenib and trametinib) works as well as taking them every day. About 280 people with advanced BRAF-mutant melanoma that cannot be removed by surgery are participating. The goal is to see if intermittent…

This study compares the drug lenalidomide to simply watching and waiting in 226 people with high-risk smoldering multiple myeloma, an early form of blood cancer. The goal is to see if lenalidomide can safely delay the cancer from becoming active and needing stronger treatment. Pa…

This study tests whether adding a radioactive drug (radium-223) to standard treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 adults with this condition will receive either the combination or cabozantinib alone. The goal is …

This study tests two oral drugs, mirdametinib and sirolimus, together in people with a specific genetic form of multiple myeloma that has returned or not responded to treatment. The goal is to find a safe dose and see if the combination can shrink or control the cancer. About 54 …

This early-phase study tested two experimental drugs, cediranib and selumetinib, in 19 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and check for side effects. The drugs work by blocking blood vessel gr…

This study tests a combination of two drugs—olaparib and radium-223—in men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The goal is to find the safest dose and see if the combo can slow the cancer's growth. About …

This study tests whether adding the drug eribulin to standard chemotherapy can help people with advanced bladder cancer live longer. It includes 184 adults whose cancer has spread and no longer responds to immunotherapy. The goal is to see if this combination works better than us…

This study tests whether combining an experimental HPV vaccine (PRGN-2009) with the immunotherapy drug pembrolizumab can boost the immune system's attack on HPV-positive throat cancer before patients receive standard treatments like surgery or chemoradiation. About 16 adults with…

This study tests whether a combination of three drugs (daratumumab, carfilzomib, and dexamethasone) can prevent or delay smoldering multiple myeloma from turning into active disease. About 14 adults with high-risk smoldering myeloma will receive the drugs in cycles, followed by d…

This study tested a drug called ibrutinib in 41 people with follicular lymphoma that returned or didn't respond to prior treatment. Ibrutinib works by blocking certain enzymes that cancer cells need to grow. The main goal was to see how many patients had their tumors shrink or di…

This study looks at whether adding an immunotherapy drug (nivolumab) to the usual two-drug treatment can better shrink tumors in people with a specific type of advanced colorectal cancer (BRAF-mutated, microsatellite stable). About 86 adults whose cancer has spread or can't be re…

This study tests whether a stem cell transplant from a matched sibling, unrelated donor, or half-matched parent can fix the immune system in people with DOCK8 deficiency, a genetic condition that causes severe infections and cancer. Participants aged 4 to 35 receive chemotherapy …

This study tests a combination of two drugs—tazemetostat and pembrolizumab—in people with advanced bladder cancer that has spread. The goal is to find the best dose and see if the combo works better than pembrolizumab alone. About 30 adults with locally advanced or metastatic uro…

This early-stage study tests a combination of targeted therapy (ibrutinib) and chemotherapy (TEDDI-R) in people with primary CNS lymphoma, a rare brain cancer. The goal is to find the safest dose and see if the treatment can control the disease. About 68 adults with relapsed or u…

This early-stage trial tests a drug called berzosertib combined with whole brain radiation for people with lung cancer that has spread to the brain. The main goal is to find the safest dose and check side effects. About 15 adults with non-small cell, small cell, or neuroendocrine…

This study tests a drug called taselisib in 70 people with advanced cancers that have a specific genetic change (PIK3CA mutation). The drug works by blocking a protein that helps cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing, but th…

This early-phase trial tests two experimental drugs, sapanisertib and telaglenastat, in people with advanced non-small cell lung cancer that has spread or come back after standard treatments. The main goals are to find the safest dose and see if the combination can shrink tumors …

This study tests whether adding olaparib to the standard chemotherapy temozolomide helps control advanced pheochromocytoma or paraganglioma—rare neuroendocrine tumors that have spread or can't be removed surgically. About 46 adults with these cancers will be randomly assigned to …

This study tests whether adding panitumumab to sotorasib works better than sotorasib alone for people with advanced solid tumors that have a specific KRAS G12C mutation. About 105 adults with cancers that have spread will receive either the combination or single drug. The goal is…

This study tests whether adding the targeted drug binimetinib to standard chemotherapy (FOLFOX) can shrink tumors or help people with advanced bile duct or gallbladder cancers live longer. About 66 adults whose cancers have a specific genetic change (MAPK pathway mutation) and ha…

This early-phase trial tests the safety and best dose of two drugs, APG-1252 and cobimetinib, given together to people whose ovarian or endometrial cancer has come back. The drugs work by blocking proteins that help cancer cells survive and grow. The goal is to see if the combina…

This early-stage trial is testing two experimental drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The main goal is to find the safest and most effective dose by monitoring side effects. Around 121 participants will take…

This study is for children and young adults (up to age 25) with a newly diagnosed, aggressive brain tumor called high-grade glioma that has a specific genetic change (BRAF V600 mutation). After standard radiation therapy, participants take two targeted pills (dabrafenib and trame…

This study aimed to test two immunotherapy drugs (tiragolumab and atezolizumab) plus targeted radiation in people with a specific, hard-to-treat type of metastatic colorectal cancer called microsatellite stable (MSS). The goal was to see if the combination could slow or stop canc…

This phase II trial tests a drug called dinaciclib in 72 people with stage IV melanoma that has spread. The drug works by blocking enzymes that help cancer cells grow. The study looks at side effects and how long patients live, aiming to control the disease rather than cure it.

This phase 3 trial tests whether adding a newer drug (venetoclax) to the standard two-drug therapy (ibrutinib plus obinutuzumab) helps prevent chronic lymphocytic leukemia (CLL) from returning in older adults (65+). It also explores if patients who respond well can safely stop ta…

This study aimed to see if a person's own immune cells, modified in a lab to target specific cancer gene mutations, could prevent advanced gastrointestinal cancers from coming back after standard treatment. It was designed for people whose blood tests showed signs of remaining ca…

This large phase 3 study compares two immunotherapy drugs (nivolumab or brentuximab vedotin) given with standard chemotherapy for people aged 12 and older with newly diagnosed, advanced-stage classical Hodgkin lymphoma. The goal is to see which combination better delays the cance…

This study tests a combination of two drugs, atezolizumab and cobimetinib, in people with advanced non-small cell lung cancer that has spread, returned, or stopped responding to standard immunotherapy. The goal is to see if this combo can shrink tumors for at least 6 months. Abou…

This study tested a drug called nivolumab in 26 people with cervical cancer that had come back or spread. Nivolumab helps the immune system attack cancer cells. The goal was to see if it could shrink tumors and control the disease, not cure it. Participants received the drug intr…

This study tests whether taking erlotinib (a daily pill that blocks cancer growth signals) after surgery helps people with a specific type of lung cancer (EGFR-mutant) live longer compared to just watching and waiting. About 390 adults with early-stage lung cancer that was fully …

This early-phase trial tests whether adding triapine to standard radioactive therapy (lutetium Lu 177 dotatate) is safe and effective for people with advanced neuroendocrine tumors of the digestive system. About 31 participants whose tumors have worsened after prior treatment wil…

This study tests whether adding the drug temsirolimus to standard chemotherapy helps people with intermediate-risk rhabdomyosarcoma (a type of muscle cancer) live longer without the cancer growing or coming back. About 325 participants up to age 40 are randomly assigned to receiv…

This study compares two drug combinations for people with advanced neuroendocrine tumors (a type of slow-growing cancer). One group gets octreotide plus interferon, the other gets octreotide plus bevacizumab. The goal is to see which combination better delays cancer growth. About…

This phase 2 trial tests whether combining nilotinib (a targeted drug) with paclitaxel (a chemotherapy drug) can shrink or slow the growth of advanced solid tumors that have worsened after prior taxane treatment. About 40 adults with various solid cancers will receive both drugs.…

This study tests whether a combination of amivantamab and hyaluronidase works as well as cetuximab for treating skin squamous cell carcinoma that has returned or spread. The trial involves 86 immunocompromised participants, such as organ transplant recipients. The goal is to comp…

This early-stage study tests a combination of two drugs, ibrutinib and lenalidomide, in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The main goal is to find the safest dose and understand side effects. About 39 participants…

This study tests a drug called MLN0128 (TAK-228) in people with advanced cancers that have a specific genetic change (mTOR mutation). The drug works by blocking enzymes that cancer cells need to grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that haven't r…

This study tests whether adding the immunotherapy drug pembrolizumab after standard chemotherapy helps prevent breast cancer from returning in people with triple-negative breast cancer. About 1,155 participants who still had cancer after chemo will receive either pembrolizumab or…

This study tests whether adding a targeted drug (ipatasertib) to standard chemotherapy (paclitaxel) can shrink or slow advanced solid tumors that have PTEN or AKT gene changes. About 33 adults with cancers that have spread or can't be removed by surgery will take part. The goal i…

This early-phase study tested a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in 19 people with advanced pancreatic cancer that had spread or could not be removed by surgery. The main goal was to find the safest dose and look at side effects. Researchers also…

This study tests whether adding a drug called uproleselan to standard chemotherapy helps older adults with acute myeloid leukemia (AML) live longer without the cancer returning. About 267 participants will receive either chemo alone or chemo plus uproleselan. The goal is to see i…

This study tests whether two immunotherapy drugs, ipilimumab and nivolumab, can shrink or slow the growth of recurrent high-grade gliomas (brain tumors) that have a high number of genetic mutations. About 37 adults with recurrent WHO grade 4 glioma will receive these drugs. The g…

This early-phase trial is testing a combination of three drugs—lenalidomide, ibrutinib, and rituximab—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatments. The main goal is to find the safest …

This early-phase study tests a new drug combination for people with advanced pancreatic cancer that has a specific marker (mesothelin). The treatment pairs a targeted chemotherapy with immunotherapy drugs and standard chemo to see if it's safe and what dose works best. About 74 a…

This study tests a drug called vorinostat in 40 people with uveal melanoma that has spread to other parts of the body. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see if the drug can shrink tumors and help control the disease.

This study looks at whether an immunotherapy drug (atezolizumab) alone or combined with chemotherapy can help control a certain type of stomach or gastroesophageal junction cancer that has a genetic feature called MSI-H/dMMR. About 240 adults with localized or locoregional cancer…

This study tested a combination of two drugs, berzosertib and irinotecan, in 17 people with advanced stomach or gastroesophageal junction cancer that had a specific genetic change (TP53 mutation) and was no longer responding to other treatments. The goal was to see if the combina…

This study tests if the immunotherapy drug nivolumab can stop or slow the growth of certain brain tumors (gliomas) that have IDH mutations. Researchers are especially interested in tumors with many genetic changes (hypermutator phenotype). The trial involves 62 adults who receive…

This phase 3 trial tests whether the immunotherapy drug pembrolizumab can prevent Merkel cell carcinoma from returning after it has been surgically removed. About 280 adults with stage I–III Merkel cell cancer will receive either pembrolizumab or standard observation. The goal is…

This early-phase trial studies the safety and best dose of adding necitumumab to osimertinib for people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. About 138 participants will receive the combination to see if it is tolerable a…

This study tests whether a combination of two immunotherapy drugs (relatlimab and nivolumab) is safer and more effective than standard chemotherapy (lomustine) for people whose glioblastoma (a type of aggressive brain cancer) has returned after initial treatment. About 184 partic…

This early-phase study tests a new drug (MLN0128) combined with bevacizumab in 50 adults with recurrent glioblastoma or other advanced solid tumors. The goal is to find the safest dose and understand side effects. This is not a cure, but aims to control tumor growth.

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps prevent cancer from returning in people with stage III colon cancer that has a specific DNA repair problem (dMMR). About 712 participants received either chemotherapy alone or chemo…

This study tests two drugs, dabrafenib and trametinib, in people with advanced cancers that have a specific genetic change called a BRAF V600 mutation. The goal is to see if these drugs can shrink tumors or stop them from growing. The trial includes 44 participants with various c…

This early-phase study tests a drug called berzosertib combined with radiation therapy for people with certain types of breast cancer that no longer respond to chemotherapy. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors better than …

This study tests a drug called rogaratinib in about 48 people with advanced sarcoma or a rare type of GIST that has certain genetic changes. The drug works by blocking proteins that help cancer cells grow. The goal is to see if it can shrink tumors or slow the disease, while moni…

This study was designed to test the drug alrizomadlin (APG-115) in people with BAP1 cancer syndrome who have early-stage mesothelioma that does not yet need standard treatment. The goal was to see if the drug could stabilize or improve the disease. However, the study was withdraw…

This study tested a drug called decitabine in 21 people with advanced myelofibrosis, a rare bone marrow cancer that causes scarring and severe anemia. The goal was to see if the drug could improve blood counts and reduce the need for transfusions. Decitabine works by reactivating…

This study tests whether adding brentuximab vedotin (a drug that delivers cancer-killing substances directly to lymphoma cells) to standard chemotherapy works better than chemo alone for children and young adults with high-risk Hodgkin lymphoma. About 600 participants with stage …

This study tests whether a very low dose of apalutamide, taken for 3-4 weeks before prostate removal surgery, can lower PSA levels in men with early-stage prostate cancer. The goal is to see if this approach might allow some men to delay or avoid surgery or radiation in the futur…

This study tests a drug called ulixertinib in people with advanced cancers that have specific changes in the BRAF gene (fusions or non-V600 mutations). The drug blocks signals that tell cancer cells to grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that ha…

This early-phase trial tested a combination of two anti-cancer drugs, pomalidomide (taken as a pill) and liposomal doxorubicin (given through an IV), in 62 adults with advanced or hard-to-treat Kaposi sarcoma, a cancer often linked to HIV. The main goals were to check the safety …

This study tests a drug called palbociclib in people with advanced cancers that have specific changes in the CDK4 or CDK6 genes. The drug works by blocking signals that tell cancer cells to grow. The goal is to see if it can shrink tumors or stop them from growing for a period of…

This study tests two new treatments—cabozantinib alone or with nivolumab—against standard chemotherapy for people with advanced non-squamous lung cancer that has returned. The goal is to see if these combinations can slow cancer growth better than current options. About 117 adult…

This study tested a combination of two drugs, trametinib and docetaxel, in 60 people with a specific genetic subtype of advanced lung cancer (KRAS mutation) that had worsened after prior treatments. The goal was to see if the combination could shrink tumors. The approach uses one…

This study tests whether adding a drug called sargramostim to two immunotherapy drugs (nivolumab and ipilimumab) helps people with advanced melanoma that cannot be removed by surgery. About 600 adults with stage III or IV melanoma will receive either the two-drug or three-drug co…

This large phase 3 trial studied nearly 5,000 people with breast cancer that had spread to lymph nodes or was at high risk of returning. Participants received standard chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) plus either bevacizumab (a drug that cuts off tumor…

This study tests whether adding a drug called copanlisib to the usual two-drug therapy (fulvestrant and abemaciclib) can better control hormone receptor-positive, HER2-negative breast cancer that has spread. About 24 adults with stage IV cancer will receive either the three-drug …

This study tests whether adding a radioactive drug (radium-223) to standard chemotherapy (paclitaxel) helps people with advanced breast cancer that has spread to the bones. The radioactive drug targets bone tumors directly, while chemo works throughout the body. About 70 particip…

This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy before surgery helps shrink tumors more than chemo alone in people with stage II-III triple negative breast cancer. About 67 participants will receive either chemo alone or chemo plus ate…

This study tests three drugs—durvalumab, olaparib, and cediranib—given together to people with advanced solid tumors or recurrent ovarian cancer. The goal is to see if these combinations can shrink tumors or slow cancer growth. Participants take the drugs by IV or mouth daily, an…

This phase II trial tests the drug olaparib in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to treatment, and whose cancer cells have a specific IDH gene change. Olaparib works by blocking enzymes that cancer cells …

This study tests whether adding the drug veliparib to standard chemotherapy (topotecan and carboplatin) helps people with advanced blood cancers like acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). About 25 adults with these cancers that have spread or no…

This study tests whether adding the immunotherapy drug nivolumab to standard chemo-immunotherapy works better than standard treatment alone for people newly diagnosed with primary mediastinal B-cell lymphoma (PMBCL), a rare type of blood cancer. About 244 participants aged 2 and …

This study tests a drug called trametinib in children and young adults (ages 1 month to 22 years) with a rare blood cancer called juvenile myelomonocytic leukemia (JMML) that has come back or not responded to standard treatment. Trametinib works by blocking certain enzymes that h…

This study tests a drug called ivosidenib in children and young adults (ages 1 to 21) whose cancers have returned or not responded to prior therapy and have a specific genetic change (IDH1 mutation). The drug aims to block a faulty signaling pathway that helps cancer grow. The ma…

This early-stage trial tests a new drug called iadademstat added to two standard chemotherapy drugs (venetoclax and azacitidine) for adults with untreated acute myeloid leukemia (AML). The main goals are to find the safest dose and check for side effects. About 45 participants wi…

This phase 2 study tests a new drug (pevonedistat) combined with two standard chemotherapies (carboplatin and paclitaxel) in 27 adults with advanced non-small cell lung cancer that has not responded to immunotherapy. The goal is to see if this combination can shrink or control th…

This early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…

This study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab works better than pembrolizumab alone for people with melanoma that can be surgically removed. About 60 adults with stage III melanoma will receive treatment before surgery to see if…

This early-phase trial tests a treatment for people with advanced solid tumors (like colorectal, lung, or breast cancer) that have a specific genetic change called KRAS. The approach uses a person's own white blood cells, which are modified in a lab to better recognize and attack…

This study tests whether adding the drug veliparib to standard chemotherapy (temozolomide) helps people with a newly diagnosed, aggressive brain cancer called glioblastoma live longer. The trial includes 447 participants whose tumors have a specific genetic change (MGMT promoter …

This study tests a combination of three drugs—dabrafenib, trametinib, and navitoclax—in people with BRAF mutant melanoma or other solid tumors that have spread or can't be removed by surgery. The goal is to find the best dose and see how well the drugs shrink tumors. About 75 adu…

This study tests whether adding the targeted drug olaparib to standard radiation therapy helps prevent inflammatory breast cancer from coming back. Inflammatory breast cancer is a rare and aggressive form of the disease. About 300 patients who have already had chemotherapy and su…

This study looks at whether adding radiation therapy to standard immunotherapy (with or without chemo) helps people with advanced non-small cell lung cancer that lacks the PD-L1 marker. About 427 adults with stage IIIB, IIIC, or IV cancer will be randomly assigned to get either t…

This study tested a drug called pazopanib against a placebo in 171 people with carcinoid tumors that were growing. The goal was to see if pazopanib could slow or stop tumor growth. Participants took the drug or placebo by mouth, and doctors tracked how long they lived without the…

This study tests a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with a type of thyroid cancer that no longer responds to radioactive iodine and has worsened after one prior targeted therapy. The goal is to see if this mix can shrink tumors or slo…

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This study tested the drug sorafenib in 38 people with advanced gastrointestinal stromal tumor (GIST) that had stopped responding to two standard treatments, imatinib and sunitinib. Sorafenib works by blocking enzymes that help tumor cells grow and by cutting off blood supply to …

This study tests whether adding the drug cediranib to standard chemotherapy (cisplatin and pemetrexed) can help people with malignant pleural mesothelioma, a rare and aggressive lung cancer. In the first phase, researchers found the safest dose of cediranib. In the second phase, …

This study tests whether a lower dose of radiation therapy combined with the immunotherapy drug nivolumab works as well as the standard radiation-plus-chemotherapy approach for people with early-stage HPV-positive throat cancer who have never smoked. About 384 participants will r…

This study tested whether a combination of ibrutinib (a targeted drug) and rituximab works better than standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. About 529 people took part. The main goal was t…

This study tests two immunotherapy drugs, nivolumab and ipilimumab, in people with advanced anal cancer that has spread and not responded to prior treatment. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. About 143 adults with this type of cancer…

This study tests whether combining two targeted drugs, trastuzumab and pertuzumab, can shrink or control tumors in people with cancers that have too much of a protein called HER2. The trial includes only cancers that are not breast, stomach, or colorectal. About 35 adults are tak…

This early-stage trial tests a new drug (CB-839 HCl) combined with two standard treatments (carfilzomib and dexamethasone) in 36 adults with multiple myeloma that has come back or stopped responding to prior therapy. The main goals are to find the safest dose and check for side e…

This early-phase study tests whether combining blinatumomab with nivolumab (and sometimes ipilimumab) is safe for people with a tough-to-treat type of leukemia that has returned or not responded to treatment. The main goals are to find the best dose and understand side effects. A…

This study tests a combination of copanlisib (a targeted drug) with two immunotherapy drugs (nivolumab and ipilimumab) in adults with advanced solid tumors that have specific gene changes (PIK3CA or PTEN). The goal is to see if the combo is safe and works better than immunotherap…

This study tests a combination of two drugs (tocilizumab and atezolizumab) plus targeted radiation in people whose glioblastoma brain tumor has returned. The goal is to make the tumor more responsive to the body's immune system. About 59 adults will take part to find the best dos…

This early-stage trial tests the safety and best dose of a drug called TAK-243 in people with acute myeloid leukemia or myelodysplastic syndromes that have returned or not responded to treatment. The drug works by blocking enzymes cancer cells need to grow. About 42 adults will t…

This study tests whether adding the immunotherapy drug nivolumab after surgery and chemotherapy can help keep non-small cell lung cancer from coming back in patients with stage IB to IIIA disease. About 900 participants who had their lung cancer completely removed are randomly as…

This study tests a new drug called bintrafusp alfa (M7824) in people with thymoma or thymic carcinoma that returned after standard platinum chemotherapy. Nine adults with advanced, inoperable disease receive the drug every two weeks. The goal is to see if the drug shrinks tumors …

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

This study tests Radium-223 in men whose prostate cancer has returned after initial treatment, but only shows up as rising PSA levels in blood—not on standard scans. The goal is to see how the drug affects the immune system and PSA levels. Participants receive up to 6 doses of Ra…

This study tests two immunotherapy drugs (tiragolumab and atezolizumab) in children and adults whose rare cancers (like atypical teratoid/rhabdoid tumor or epithelioid sarcoma) have returned or not responded to treatment. These cancers lack certain genes (SMARCB1 or SMARCA4), mak…

This study tested a combination of two drugs—cetuximab and interleukin-12—in 23 people with head and neck cancer that had spread, returned, or could not be surgically removed. The goal was to find the safest dose of interleukin-12 and see if the pair could shrink tumors. The appr…

This study was designed for people with muscle-invasive bladder cancer who cannot receive the standard chemotherapy drug cisplatin. It aimed to compare the effects of taking erdafitinib alone versus erdafitinib combined with atezolizumab before surgery. However, the trial was wit…

This study tests whether adding the immunotherapy drug atezolizumab to the standard drug cabozantinib works better than cabozantinib alone for people with advanced papillary kidney cancer that has spread. About 200 participants will receive either the combination or the single dr…

This early-phase trial tested a combination of two drugs—veliparib and carboplatin—in 44 people with HER2-negative breast cancer that had spread. The goal was to find the best dose and check safety. Carboplatin damages cancer cell DNA, and veliparib may stop the cancer from repai…

This study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …

This study tests a combination of three drugs—ipilimumab, nivolumab, and brentuximab vedotin—in people with Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to find the safest doses and see how well the drugs work together to shrink or kill can…

This early-stage trial tests whether combining two drugs, azacitidine and abatacept, can shrink tumors in adults with T-cell lymphoma that has come back or not responded to prior therapy. About 20 participants will receive the drugs in 28-day cycles for up to 13 cycles. The study…

This study tests a powerful chemotherapy combination (Hyper-CVAD) plus the targeted drug dasatinib, with or without a donor stem cell transplant, for people with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this approach can keep …

This study tests a drug called palbociclib in 40 adults with advanced cancers that have specific genetic changes (CCND1, 2, or 3 amplification). The drug blocks certain proteins that help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse…

This early-phase trial tests adding an experimental drug (berzosertib) to standard chemotherapy (carboplatin and gemcitabine) for people with ovarian, peritoneal, or fallopian tube cancer that has returned and spread. The main goals are to find the safest dose and check for side …

This study tests a treatment plan tailored to each child's risk level for a rare liver cancer called hepatoblastoma. About 236 children will receive standard treatments like surgery and chemotherapy, plus the drug temsirolimus for high-risk cases. The goal is to see if this appro…

This study tested a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in 17 people with a rare, fast-growing type of neuroendocrine cancer that had spread. The goal was to see if the drugs could shrink tumors by blocking cancer growth and boosting the immune sy…

This study tests whether adding the immunotherapy drug nivolumab after standard chemo-radiation helps people with HPV-positive throat cancer live longer without their cancer returning. About 636 adults with intermediate-risk, locally advanced disease are being followed. The goal …

This early-stage trial tests a new drug, lintuzumab-Ac225, for people with a high-risk blood cancer called myelodysplastic syndrome (MDS) that hasn't improved with standard treatments. The drug works like a smart bomb: it attaches to cancer cells and delivers radiation directly t…

This study tests a drug called olaparib in people with advanced bladder or related cancers that have specific DNA-repair defects. The drug works by stopping cancer cells from fixing their damaged DNA, which may cause them to die or stop growing. About 60 participants will receive…

This study tested two drugs, olaparib and ceralasertib, in 24 people with advanced solid tumors (like bile duct cancer) that have a specific IDH gene mutation. The goal was to see if the combination could shrink or stop the growth of these hard-to-treat cancers. The trial is no l…

This study tests whether adding the immunotherapy drug blinatumomab to standard chemotherapy helps adults with a certain type of leukemia live longer and stay cancer-free longer. About 488 newly diagnosed patients took part. The goal is to see if the combination works better than…

This study tested a combination of two drugs, olaparib and cediranib, in 70 people with ovarian, fallopian tube, or peritoneal cancer that had come back after initial treatment. The goal was to see if the drugs could slow or stop cancer growth by blocking enzymes that cancer cell…

This early-phase trial tests a new treatment for adults with B-cell cancers (like leukemia or lymphoma) that haven't improved with standard care. The approach uses a patient's own immune cells, modified in a lab to target and kill cancer cells. The main goal is to check if the tr…

This study tests whether adding veliparib to the chemotherapy drug temozolomide helps people with small cell lung cancer that has returned or stopped responding to treatment. About 97 participants receive either the combination or a placebo plus temozolomide. The goal is to see i…

This early-phase trial tests a personalized cell therapy called GD2CART for children and young adults with osteosarcoma or neuroblastoma that has returned or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to recognize and attack ca…

This study tests whether adding the drug bortezomib to standard chemotherapy helps children and young adults (ages 1 to 30) with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. About 847 participants received either standard chemo alone or ch…

This early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…

This early-phase trial tested a combination of two drugs, erlotinib and irinotecan, in 60 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Researchers also looked for signs …

This study looks at a rare, often fatal disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers want to learn how the disease works and test several experimental drug combinations, including zidovudine, valganciclovir, bortezomib, and…

This study tests a drug called GSK2636771 in 35 adults with advanced cancers that have lost the PTEN protein. The drug blocks a protein (PI3K-beta) that helps these cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. This is a phase II t…

This study tests a combination of three drugs (entinostat, PDS01ADC, and bintrafusp alfa) in adults with advanced cancers linked to HPV or certain colon cancers that haven't responded to standard treatments. The goal is to find a safe dose and see if the combo can shrink tumors. …

This large phase 3 trial studies whether adding the drug blinatumomab to standard chemotherapy can better treat newly diagnosed B-cell leukemia or lymphoma in children and young adults, including those with Down syndrome. The study involves over 6,700 participants and assigns dif…

This early-phase study tests the safety of combining two drugs, moxetumomab pasudotox and rituximab, for people with hairy cell leukemia that has not responded to standard treatment. About 18 adults will receive up to 8 cycles of the drugs through an IV. The main goal is to find …

This early-stage trial is testing the safety and potential benefit of pembrolizumab, an immunotherapy drug, in 71 children whose brain tumors (like DIPG, high-grade gliomas, or medulloblastoma) have come back or not responded to standard treatments. The drug works by helping the …

This study compares a targeted immunotherapy drug called blinatumomab to standard chemotherapy in 669 children and young adults (ages 1 to 30) whose B-cell acute lymphoblastic leukemia has returned after initial treatment. The goal is to see if blinatumomab can help the immune sy…

This study tests a drug called GSK2636771 in people with advanced cancers that have a specific genetic change (PTEN mutation or deletion). The drug blocks a protein that may help these cancer cells grow. Researchers want to see if the drug can shrink tumors or stop them from grow…

This study tests a combination of two drugs (peposertib and avelumab) plus a special type of radiation for people with advanced solid tumors or bile duct cancers that have spread. The goal is to find the best dose and see if the treatment can shrink tumors or stop them from growi…

This study tests whether adding a drug called tuvusertib (which blocks a DNA repair enzyme) to the immunotherapy avelumab can slow down advanced Merkel cell cancer that has stopped responding to standard immunotherapy. About 50 adults with this rare skin cancer will be randomly a…

This study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…

This phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…

This study compares two types of PET scans to see which better finds prostate cancer that has spread. About 96 adults with metastatic prostate cancer will receive an experimental radiotracer (18F-DCFPyL) and a standard one (18F-NaF) on different days, then have whole-body scans. …

This study compares the accuracy of HPV testing using self-collected vaginal samples versus samples collected by a doctor during a pelvic exam. About 500 people referred for colposcopy or cervical procedures will participate. The goal is to see if self-collection is a reliable al…

This study tests whether women can collect their own vaginal samples for HPV testing as accurately as a doctor's sample. It involves 750 women already referred for colposcopy or cervical procedures. The goal is to make cervical cancer screening easier and more comfortable, potent…

This study looks at whether women can collect their own vaginal samples for HPV testing instead of having a doctor do it during a pelvic exam. About 500 people referred for a colposcopy will provide both a self-collected sample and a doctor-collected sample. The goal is to see if…

This study tests a radioactive tracer called 18F-DCFPyL to see if it can better find prostate cancer that has spread or come back after treatment. About 360 men with high-risk newly diagnosed or recurrent prostate cancer will get a PET/CT scan with this tracer. The goal is to imp…

This study is testing whether a special PET scan called FES PET/CT can predict how well hormone therapy will work for people with newly diagnosed breast cancer that has spread. The scan uses a radioactive form of estrogen to light up cancer cells that respond to hormones. About 9…

This early-phase trial tests a MUC1 peptide vaccine in 50 current or former smokers at high risk for lung cancer. The vaccine aims to train the immune system to recognize and attack precancerous cells before they become cancer. The study focuses on safety and whether the vaccine …

This study tests a special vaccine (Tri-Ad5) plus an immune booster (N-803) to see if it can prevent colon and other cancers in people with Lynch syndrome, a genetic condition that raises cancer risk. The vaccine trains the immune system to recognize and destroy precancerous cell…

This study tests whether a daily broccoli seed and sprout extract (BSSE) can boost firefighters' natural ability to remove cancer-causing toxins from their bodies. Firefighters are often exposed to harmful chemicals like benzene, which increases their cancer risk. 72 firefighters…

This study tests whether simvastatin, a widely used cholesterol medication, can prevent liver cancer in 52 adults with liver cirrhosis. Participants take simvastatin to see if it slows or stops the liver from developing cancer. The goal is to find a simple, affordable way to redu…

This phase 2 trial tests whether taking aspirin can stop Barrett's esophagus from returning after it has been successfully removed with radiofrequency ablation. About 21 adults who had complete removal of Barrett's esophagus will take either aspirin or a placebo for 12 months. Re…

This study tests whether curcumin, a compound found in turmeric, can prevent stomach cancer in people with chronic atrophic gastritis or gastric intestinal metaplasia. About 50 participants will receive either curcumin or a placebo for a period, and researchers will measure chang…

This study tests whether a single dose of the HPV vaccine can protect young women aged 18-30 from cervical cancer. Researchers in Costa Rica are giving 5,000 women either one HPV shot or a placebo to see if one dose is enough to prevent persistent HPV infections that can lead to …

This study looks at whether taking aspirin at certain times can help prevent colorectal cancer in people who have had colorectal adenomas (precancerous growths). The researchers are measuring changes in cell growth and death in the colon lining. The study involves 81 adults and i…

This study tests whether metformin, a drug typically used for diabetes, can prevent oral cancer in people with precancerous mouth lesions like leukoplakia or erythroplakia. The trial enrolled 26 participants and measured if the lesions shrank or disappeared. The goal is to find a…

This early-stage study tests an oral drug called ropidoxuridine (IPdR) combined with whole brain radiation in people whose cancer has spread to the brain. The goal is to find the safest dose and see if the drug makes radiation more effective at killing tumor cells. About 11 adult…

This study looks at whether acceptance and commitment therapy (ACT) can improve sleep for adults with sickle cell disease. Participants will have weekly video chats with a coach for 8 weeks and wear a wrist device to track sleep. The goal is to see if this approach is practical a…

This early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…

This study examines tumor samples from 170 cancer patients who had unusually good responses to treatments that failed for most others. Researchers analyze the DNA of these tumors to find genetic changes that might explain why these patients did so well. The goal is to discover bi…

This study is developing a questionnaire specifically for children and teens (ages 5-17) who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant. The goal is to create a tool that accurately captures how bothersome their symptoms are, since current scales …

This study looks at information already collected from over 566,000 AARP members aged 50 to 71. Researchers want to learn how diet and lifestyle choices are linked to cancer, chronic diseases, and death. No new participants are being recruited, and no treatments are being tested.

This study reviews medical records from 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, such as inflammation and immune reactions, and what factors influence them. No new treatments or pa…

This study screens up to 8300 people with early-stage non-small cell lung cancer (stages IB to IIIA) whose tumor has been or will be removed by surgery. Researchers analyze the tumor's genes to find specific mutations, which helps doctors choose the most effective targeted therap…

This study looked at whether routine screening for prostate, lung, colorectal, and ovarian cancers can lower the number of deaths from these diseases. Over 154,000 people took part, with some getting regular screening and others receiving usual care. The main goal was to see if e…

This study collects blood and urine samples from 1,000 adults who are receiving radiation therapy for cancer. Researchers want to learn how radiation affects genes in white blood cells, damages red blood cells, and changes hormone levels. Samples are taken before, during, and aft…

This study aims to collect and store blood, urine, and tumor tissue samples from 500 adults with breast, ovarian, or uterine cancer, as well as some of their biological relatives. The samples will be used to study DNA changes that cause cancer, helping researchers guide future tr…

This study collects leftover tissue and blood samples from 1,200 adults with known or suspected cancer during their standard surgeries or biopsies. Researchers will compare cancerous and normal tissues to find differences that could lead to new cancer treatments. No extra procedu…

This study looks at why people with HIV and certain cancers caused by KSHV (Kaposi sarcoma herpesvirus) may lose bone density faster. Researchers will review past CT scans and health records from 40 adults treated at the NIH between 2005 and 2020. The goal is to find factors link…

This study collects blood and bone marrow samples from up to 550 people with blood cancers like leukemia and lymphoma. Researchers will study the samples in the lab to learn more about how these cancers grow and differ from normal cells. The goal is to better understand the disea…

This study collects blood samples from people who have unexpected or severe side effects from drugs they are taking in other NIH trials. The goal is to measure drug levels in the blood to better understand why side effects happen. About 100 participants aged 2 and older will take…

This study does not offer new treatment. Instead, it follows up to 1,150 people who previously received experimental cell or gene therapy for cancers like melanoma or neuroendocrine tumors. Participants will have yearly physical exams and blood tests for up to 15 years to monitor…

This study looked at whether regular screening tests for ovarian cancer can help find the disease early and reduce deaths. Over 78,000 women took part, with some getting screened and others receiving usual care. The goal was to see if screening makes a difference in survival rate…

This study looks back at medical records from about 1,000 children and adults with adrenocortical carcinoma (ACC), a rare and serious adrenal gland cancer. Researchers want to see how factors like age, sex, race, and tumor burden relate to survival and treatment response. No new …

This study aims to learn more about primary liver cancer by collecting blood, urine, stool, and tissue samples from 132 adults who have had or will have immunotherapy. Researchers will analyze these samples to understand how the disease develops and progresses. Participants do no…

This study tests if a small, wearable patch called TempTraq can detect fevers earlier than standard checks in cancer patients receiving immunotherapy. Early detection of fever may help prevent severe cytokine release syndrome (CRS), a serious side effect. About 136 adults with ca…

This study follows thousands of women in Costa Rica who received the HPV vaccine (types 16 and 18) and compares them to unvaccinated women. Researchers want to see how long the vaccine protects against cervical cancer and related diseases, and whether it might lead to more infect…

This study explores whether a special PET/CT scan using a radioactive tracer called FLT can help doctors see how well chemotherapy is working in people with acute myeloid leukemia (AML). About 87 adults with newly diagnosed AML will get an FLT PET/CT scan after starting treatment…

This study looks at whether matching cancer treatment to a patient's unique tumor genes works better than standard care. Over 6,400 adults with advanced cancers that no longer respond to treatment will have their tumors genetically tested. Based on the results, they receive a tar…

This study looked at whether regular screening for prostate, lung, colorectal, and ovarian cancers helps prevent death from these diseases. About 155,000 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers tracked cancer cases…

This study explores whether a computer algorithm called ENLIGHT can help choose already-approved drugs for people with advanced breast cancer that has stopped responding to treatment. About 175 adults with triple-negative or hormone-resistant breast cancer will have their tumor t…

This study follows 259 people with NF1 over up to 10 years to learn how the disease changes over time. Participants get regular check-ups, scans, and tests to track tumors, pain, and quality of life. The goal is to gather information that will help design better treatments in the…

This study looks at people and families who may have a higher chance of developing blood or lymph node cancers, like leukemia or lymphoma. Researchers want to learn about the genes, environment, and other factors that raise this risk. Participants fill out health questionnaires, …

This study looks at whether combining a genetic test (called the Genomic Prostate Score, or GPS) with MRI scans can help doctors better choose which men with prostate cancer are good candidates for focal therapy—a treatment that targets only the cancerous part of the prostate. Re…

This study aims to find genetic changes linked to chordoma, a rare and serious bone cancer. Researchers will collect saliva and medical history from 188 people in the U.S. or Canada who have chordoma but no family history of it. The goal is to learn how often certain gene alterat…

This study follows up to 500 children who received gene therapy for cancer through the National Cancer Institute. Researchers will monitor them for 15 years to detect any delayed side effects from the treatment. Participants will have regular check-ups and blood tests to track th…

This early-phase trial tests the drug triapine in 12 people with a rare type of uterine cancer (serous adenocarcinoma). Participants receive one dose of triapine before their scheduled hysterectomy. Researchers then examine the removed tumor tissue to see if the drug affects canc…

This study tested whether routine screening for four cancers (prostate, lung, colorectal, and ovarian) can reduce deaths from these diseases. Over 154,000 adults aged 55 to 74 took part. Researchers compared cancer deaths between those who got screened and those who received usua…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will track these samples over time to learn how cancer changes and why some treatments stop working. The goal is to build a resource for futu…

This study tracks a substance called 2-HG in the brains of people with a type of brain cancer (glioma) that has specific gene changes. By using special MRI scans over time, researchers hope to learn how and when these tumors become more aggressive. About 42 adults will have regul…

This study looks back at the medical records of 232 adults with cancer who took the immunotherapy drug M7824. The goal is to make a complete list of all side effects caused by the drug. By understanding these side effects, doctors hope to prevent or reduce them in future cancer t…

This study does not provide any new treatment. It follows up to 1,000 adults who previously received CAR T-cell gene therapy for blood cancers like lymphoma, leukemia, or multiple myeloma. The goal is to watch for long-term side effects, as required by regulators. Participants wi…

This study collects white blood cells and tumor cells from cancer patients, and white blood cells from healthy volunteers, to help researchers grow anti-cancer cells in the lab. The goal is to create experimental cell therapies for future use. Up to 7,000 participants will provid…

This study looks at adults who grew up on farms to see if early exposure to pesticides and other farm-related factors is linked to cancer. Researchers will collect online surveys and biological samples from over 64,000 participants and track their health over many years. The goal…

This early-stage study looks at whether the drug abemaciclib can get into brain tumors in people with recurrent high-grade glioma or diffuse midline glioma. Participants take the drug for a few days, then have surgery to place a tiny tube in the brain that collects fluid samples …

This study provides standard cancer care to patients at the National Cancer Institute while collecting their medical information for research. It is open to adults and children with cancer or HIV, including those with rare diseases or who cannot get proper care elsewhere. The goa…

This early-phase trial looks at how the drug DS-8201a affects tumor cells and the immune system in people with advanced HER2-positive cancers that have stopped responding to standard treatments. About 62 adults with solid tumors that have spread or cannot be removed will have tum…

This study follows adults who previously received gene therapy as part of a National Cancer Institute study. Researchers will contact participants yearly for up to 15 years to check for any long-term side effects, such as new cancers or blood disorders. Participants may give bloo…

This early-phase study looked at how the body handles two different doses of vorinostat when given with standard chemotherapy drugs (carboplatin or paclitaxel) in 20 adults with advanced solid tumors that had no standard treatment options. The main goal was to measure drug levels…

This study looks at whether a high-fiber, plant-based diet and regular exercise can change the gut microbiome in adults with melanoma who are receiving immunotherapy. Participants will be split into two groups: one follows a strict diet and exercise plan, the other gets standard …

This study was designed to learn how well the healthcare system supports adolescents and young adults (ages 12-39) with advanced or recurrent cancer, focusing on their emotional, spiritual, and communication needs. It also aimed to uncover differences in care quality for Black, A…

This study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are frozen and stored for later use in making a personalized therapy called CAR T-cells. The goal is to have these cells ready so …

This study is checking how long the HPV vaccine protects women who received one, two, or three doses. Researchers are following about 946 women from an earlier trial in Costa Rica for up to 20 years after their shots. By testing blood samples, they hope to learn if one dose might…

This study creates a bank of blood, cheek cells, semen, urine, or nail clippings from up to 1,200 healthy adult volunteers. The samples are used by scientists for lab research only, such as studying immune function or developing tests. Donors are paid for their time and must be N…

This study tests whether a special PET scan, done before prostate removal surgery, can predict if prostate cancer will come back. About 175 men with high-risk prostate cancer will get the scan, then have surgery, and be followed for up to 5 years. The goal is to see if this scan …

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This study looked at whether regular screening tests for prostate, lung, colorectal, and ovarian cancers can help find cancer early and reduce deaths. Over 76,000 men and women took part, with some getting screened and others receiving usual care. The main goal was to see if scre…

This study follows nearly 1,900 cancer patients who tested positive for COVID-19. Researchers collect blood samples, medical records, and images to see how the virus impacts their cancer treatment and overall health. The goal is to learn which factors make COVID-19 more severe in…

This study follows nearly 90,000 farmers, their spouses, and pesticide applicators in Iowa and North Carolina over many years. Researchers track who develops cancer or other diseases and compare that to their exposure to pesticides and other farm chemicals. The goal is to identif…

This study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…

This study screens children and young adults (ages 1-21) with advanced solid tumors, lymphomas, or related disorders that have not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be targeted by exis…